Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals

AIDS

Volumn 24, Issue 18, 2010, Pages 2789-2796

  Manak, Mark M ^a   Moshkoff, Dmitry A ^a   Nguyen, Lequan T ^a   Meshki, John ^b   Tebas, Pablo ^c   Tuluc, Florin ^b,c   Douglas, Steven D ^b,c  

^a Genomics Collaborative   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiretroviral drugs; Aprepitant; Human immunodeficiency virus type 1; Neurokinin 1 receptor antagonists; Synergy

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANTIRETROVIRUS AGENT; APREPITANT; L 759274; LAMIVUDINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SUBSTANCE P; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CELL CULTURE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ENTRY;

ANTI-HIV AGENTS; BLOOD-BRAIN BARRIER; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM DISEASES; DRUG INTERACTIONS; HIV INFECTIONS; HIV-1; HUMANS; MORPHOLINES; RECEPTORS, NEUROKININ-1; SIGNAL TRANSDUCTION; SUBSTANCE P;

EID: 78549255861     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283405c33     Document Type: Article

References (28)

1. McGillis JP, Organist ML, Payan DG. Substance P and immunoregulation. Fed Proc 1987; 46:196-199.
2. Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 2009; 30:271-276.
3. Kennedy PG, Rodgers J, Jennings FW, Murray M, Leeman SE, Burke JM. A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Proc Natl Acad Sci U S A 1997; 94:4167-4170.
4. Lai JP, Lai S, Tuluc F, Tansky MF, Kilpatrick LE, Leeman SE, Douglas SD. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci U S A 2008; 105:12605-12610.
5. Patel L, Lindley C. Aprepitant: a novel NK1-receptor antagonist. Expert Opin Pharmacother 2003; 4:2279-2296.
6. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71:7478-7487.
7. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K. The neuropeptide substance P activates transcription factor NFkappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 1997; 159:4952-4958.
8. Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, Douglas SD. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc Natl Acad Sci U S A 2001; 98:3970-3975.
9. Wang X, Douglas SD, Lai JP, Tuluc F, Tebas P, Ho WZ. Neurokinin-1 receptor antagonist (aprepitant) inhibits drugresistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol 2007; 2:42-48.
10. Wang X, Douglas SD, Song L, Wang YJ, Ho WZ. Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages. J Neuroimmune Pharmacol 2008; 3:257-264.
11. Ho WZ, Kaufman D, Uvaydova M, Douglas SD. Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages. J Neuroimmunol 1996; 71:73-80.
12. Douglas SD, Cnaan A, Lynch KG, Benton T, Zhao H, Gettes DR, Evans DL. Elevated substance P levels in HIV-infected women in comparison to HIV-negative women. AIDS Res Hum Retroviruses 2008; 24:375-378.
13. Douglas SD, Ho WZ, Gettes DR, Cnaan A, Zhao H, Leserman J, et al. Elevated substance P levels in HIV-infected men. AIDS 2001; 15:2043-2045.
14. Li Y, Douglas SD, Song L, Sun S, Ho WZ. Substance P enhances HIV-1 replication in latently infected human immune cells. J Neuroimmunol 2001; 121:67-75.
15. Stalmeijer EH, Van Rij RP, Boeser-Nunnink B, Visser JA, Naarding MA, Schols D, Schuitemaker H. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol 2004; 78:2722-2728.
16. Santoni G, Perfumi MC, Spreghini E, Romagnoli S, Piccoli M. Neurokinin type-1 receptor antagonist inhibits enhancement of T cell functions by substance P in normal and neuromanipulated capsaicin-treated rats. J Neuroimmunol 1999; 93:15-25.
17. Castro BA, Weiss CD, Wiviott LD, Levy JA. Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells. J Clin Microbiol 1988; 26:2371-2376.
18. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48:4827-4833.
19. Chernova I, Lai JP, Li H, Schwartz L, Tuluc F, Korchak HM, et al. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J Leukoc Biol 2009; 85:154-164.
20. Tsien RY. New tetracarboxylate chelators for fluorescence measurement and photochemical manipulation of cytosolic free calcium concentrations. Soc Gen Physiol Ser 1986; 40:327-345.
21. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, et al. Administration of 30-azido-30-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1:575-580.
22. Broder S, Fauci AS. Progress in drug therapies for HIV infection. Public Health Rep 1988; 103:224-229.
23. Palma C, Nardelli F, Manzini S, Maggi CA. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer 1999; 79:236-243.
24. Regoli D, Boudon A, Fauchere JL. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994; 46:551-599.
25. Fong TM, Yu H, Huang RR, Strader CD. The extracellular domain of the neurokinin-1 receptor is required for highaffinity binding of peptides. Biochemistry 1992; 31:11806-11811.
26. BergmanAJ,Marbury T, Fosbinder T,Swan S,Hickey L, Bradstreet TE, et al. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005; 44:637-647.
27. Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32:1287-1292.
28. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44:190-194.